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1. Introduction
  Ayurveda, the South Asian system of medicine mainly 
uses plant-based drugs or formulations to treat various 
ailments including cancer. Plant derived compounds 
have a special place in anti-cancer therapy, and some of 
new chemotherapeutic agents are currently available for 
use in a clinical setting include paclitaxel, vincristine, 
podophyllotoxin and camptothecin, a natural product 
precursor for water soluble derivatives[1-3]. Due to lack of 
effective drugs, cancer is a fatal disease rating the top three 
cause of death. Many of the chemotherapeutic agents for 
the treatment of cancer are highly expensive, mutagenic, 
carcinogenic and teratogenic and marrow inhibition limits 
their applications[4]. Therefore the quest for effective anti-
cancer drug is an active research field. Efforts are being 
made to identify naturally occurring anti-carcinogens, 
which would prevent, slow/reverse cancer development[5]. 
Plants, vegetables and herbs used in the folk and traditional 
medicine have been accepted currently as one of the main 
source of cancer chemoprevention drug development[6]. 
The plant Alpinia calcarata Rosc. belongs to the family, 
Zingiberaceae popularly known as Sugondha Boss (Bengali) 
has a widespread occurrence in Bangaldesh, India, Sri 
Lanka, Malaysia, China, and Timor. Compounds isolated 
from Zingiberaceae plants were found to have anticancer 
activity against various cell lines and also have strong 
antioxidant, anti-inflammatory activity[7-13]. Some novel 
compounds have DNA topoisomerase II poisoning activity 
and can induce apoptosis[14]. Here the plant selected is used 
in traditional medicine for the treatment of various ailments 
such as a warming digestive tonic, carminatve, stomachic, 
expectorant, stimulant and antifungal agent[15]. It is also 
used as tonic, aphrodisiac and diuretic, and in the treatment 
of headache, lumbago diabetes, chest pain, rheumatic 
pains, bronchitis, dyspepsia, sore throat, impotence and 
diseases of the kidney and liver. It is particularly reputed 
for its efficacy in chest complain[16]. Rhizome of the 
plant also possesses several diterpenoids, some of which 
are cytotoxic, and can induce cell cycle arrest such as 
Calcaratan D, Calcaratan E[17-19]. Alpinia calcarata Rosc. 
shows potent antibacterial activity against some pathogenic 
gram positive and gram negative bacteria[20]. The essential 
oils of the plant have significant repellant properties against 
Periplanteta americana[21]. It also posses antituberocolin 
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property[22]. Hot water and ethanolic extracts of Alpinia 
calcarata rhizomes have dose dependent antinociceptive 
activity[23]. However, their anticancer activity has not been 
investigated so far. From this viewpoint the present study 
was carried out to evaluate the anti-tumor activity of ethanol 
extract of Alpinia calcarata Rosc (EEAC) against Ehrlich 
ascites carcinoma (EAC) in Swiss albino mice.                                                        
2. Materials and methods
2.1. Materials
  The dried powder material of the rhizome of Alpinia 
calcarata Rosc was extracted with ethanol (yield 9.25%). 
The ethanol extract was then distilled, evaporated, 
and dried invacuum. The crude extract was dissolved 
in dimethylsulfoxide (DMSO) for the experiments. For 
therapeutic treatment, crude ethanol extract was dissolved 
in DMSO (10%) at the concentration of 0.5 mg/mL, 1 mg/mL 
and 2 mg/mL.
2.2. Chemicals and reagents
  All the chemicals and reagents used throughout the 
investigation were of reagent grade. Ethanol and sodium 
chloride were purchased from MERCK, Merck KGaA, 64271 
Darmstadt, Germany; DMSO, hydrochloric acid (6M) from 
BDH Laboratory supplies, Roole, BH 15, England; bleomycin 
and cells counting fluids (WBC, RBC fluids) from Sigma-
Aldrich Chemie GmbH, Taufkirchen, Germany.
2.3. Animals
  Adult Swiss albino male mice (20-25 g) were used through 
out this study. They were obtained from International Center 
for Diarrheal Diseases Research, Bangladesh (ICDDRB). 
Animals were fed with standard mouse-pellets (collected 
from ICDDRB) and water was given in ad libitum. 
2.4. Tumor cells
  Ehrlich ascites carcinoma (EAC) cells were obtained by the 
courtesy of Indian Institute for Chemical Biology, Kolkata, 
India and were maintained by weekly intraperitoneal (i.p.) 
inoculation of 105 cells/mouse in the laboratory.
2.5. Ethical clearance
  Protocol used in this study for the use of mice as animal 
model for cancer research was approved by the Institutional 
Animal, Medical Ethics, Biosafety and Biosecurity 
Committee (IAMEBBC) for Experimentations on Animal, 
Human, Microbes and Living Natural Sources (225/320-
IAMEBBC/IBSc), Institute of Biological Sciences, University 
of Rajshahi, Bangladesh.
2.6. Determination of median lethal dose (LD50)
  An acute toxicity study relating to the determination of 
LD50 was performed[24]. The crude EEAC was dissolved in 
2% DMSO and injected intraperitoneally to 8 groups of mice 
(each containing n=6) at different doses (100, 150, 200, 
250, 300, 400, 500 and 600 mg/kg). LD50 was evaluated by 
recording mortality after 24 hours.
2.7. Cell growth inhibition
  In vivo tumor cell growth inhibition was carried out by 
the method as described by Sur et al[25]. For this study, 5 
groups of mice (6 in each group) were used. For therapeutic 
evaluation 14伊105 cells/mouse were inoculated in to each 
group of mice on the first day. Treatment started after 24 h 
of tumor inoculation and continued for 5 days. Group 1 to 
3 received the crude extract (EEAC) at the doses 2 mg/kg,
4 mg/kg and 8 mg/kg, respectively per day per mouse. In 
each case the volume of the test solution injected (i.p.) 
were 0.1 mL/day per mouse. Group 4 received bleomycin
(0.3 mg/kg, i.p.) and finally the group 5 was treated with the 
vehicle (normal saline) and was considered as untreated 
control. The mice were sacrificed on the 6th day after 
transplantation and tumor cells were collected by repeated 
intraperitoneal wash with 0.9% saline. Viable tumor cells 
per mouse of the treated group were compared with those of 
control.
  The cell growth inhibition was calculated by using the 
formula: 
 % Cell growth inhibition = (1- 
Tw
Cw
伊100)  
  Where, Tw = Mean of number of tumor cells of the treated 
group of mice and Cw = Mean of number of tumor cells of 
the control group of mice.
2.8. Bioassay of EAC cells (Transplantation ability of EAC 
cells)
  The effect of EEAC on transplantability of EAC cells was 
carried out by the method as described in the literature[26]. 
In this experiment two groups of mice (n=4) were inoculated 
with 115伊105  EAC cells. Group 1 was treated with the test 
compound at the dose of 8 mg/kg for 5 consecutive days 
and group 2 served as control. On day 7, tumor cells from 
the mice were harvested in cold (0.9%) saline, pooled, 
centrifuged and re-inoculated into two fresh groups of mice 
(n=4) as before. No further treatment was done on these 
mice. On day 5, they were sacrificed and viable tumor cells 
count/mice were estimated.
2.9. Average tumor weight and survival time (MST)
  These parameters were measured under similar 
experimental conditions as stated in the previous 
experiment. Tumor growth was monitored daily by 
measuring weight change. The host survival time was 
recorded and expressed as MST in days and percent increase 
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of life span was calculated[27] as follows:
MST = 
暺Survival time (days) of eac h mouse in a group
Total mumber of mice 伊100
Percent increase of life span % = 
MST of treated group
MST of control group
伊100( )
2.10. Haematological studies
  The haematological parameters viz, WBC, RBC, Hb content, 
differential counts etc. were determined by the standard 
methods using cell dilution fluids and haemocytometer[28,29]. 
For this purpose, blood was collected from the mouse by 
tail puncture method. Three groups of mice (with n=4) were 
taken for doses 2, 4 and 8 mg/kg of the extract. Treatment 
started after 24 hours of tumor transplantation and was 
continued for 10 consecutive days. On day 12, the blood 
parameters were assayed.
  For normal mice, four groups (n=4) were taken for the 
purpose. The blood from the mice of groupⅠ was assayed 
on day 0 (without any treatment). The second and third 
groups of mice were treated with extract at dose 8 mg/kg 
for 5 and 10 consecutive days, respectively and analyzed as 
before. The mice of 4th group were treated with 50 mg/kg 
for 10 consecutive days and assayed on day 25.
2.11. Brine shrimp lethality bioassay
  Cytotoxicity of the compound was screened against Artemia 
salina in a 1-day in vivo assay[30] according to published 
protocol. For the experiment 3 mg of the compound was 
dissolved in 0.6 mL (600 毺L) of distilled water to get a 
concentration of 5 毺g/毺L and by serial dilution technique, 
solutions of varying concentrations such as 5, 10, 20, 40, 80 
and 100 毺g/mL were obtained. After 24 h of incubation, 
the vials were observed using a magnifying glass and the 
number of survivors in each vial were counted and noted. 
From this data, the percentage of mortality of the nauplii 
was calculated for each concentration and the LC50 value 
was determined using Probit analysis as described in the 
literature[31].
2.12. Statistical analysis
  The experimental results have been expressed as the 
mean依SEM. Data have been calculated by one way ANOVA 
followed by Dunnett ‘t’ test using SPSS software of 10 version. 
Value at P<0.05 was considered as significant.
3. Results 
  Maximum cell growth inhibition (85.7%) was found after 
treatment with dose 8 mg/kg whereas 69.3% and 34.5% cell 
growth inhibition were observed at dose 4 mg/kg, and 2 mg/
kg, respectively.  Bleomycin at dose 0.3 mg/kg on the other 
hand inhibited the cell growth by 93.7%. EAC cell growth 
inhibition by EEAC was quite comparable to the standard 
anticancer drug bleomycin.       
  The transplantability of EAC cells were remarkably 
inhibited by EEAC since the reduction in EAC cell growth as 
high as 54.78% was observed, when 6 days treated EAC cells 
were reinoculated into fresh mice (viable cells counts were 
performed on day 5).
  In vivo MST of the untreated tumor bearing mice was (20.5依
1.4) days. With the treatment of EEAC, this value increased 
markedly. About 70.25% enhancement of MST was found at 
dose 8 mg/kg. EEAC at dose 4 mg/kg and 2 mg/kg increased 
the MST by 57.3% and 28.4%, respectively; whereas 
bleomycin at dose 0.3 mg/kg increased the MST value by 
88.4%.
  The treatment with EEAC also reduced the rate of tumor 
growth. It was found to be only 28% at dose 8 mg/kg  after 20 
days as against 92% without any treatment. With bleomycin 
(0.3 mg/kg) however the growth rate reduced to 21% in 20 
days (Figure 1).
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Figure 1. Effect of EEAC on tumor weight in mice. 
*P<0.05,** P <0.01 and*** P <0.001 compared with control group.
  The haematological parameters of both treated and non-
treated mice were examined. In EAC cell bearing mice all the 
parameters such as haemoglobin, WBC, RBC and differential 
counts (monocytes, lymphocytes, neutrophil, monocytes) 
were significantly changed as compared to those of the 
normal mice. These parameters reverted towards normal 
values when treated with the extract at dose 8 mg/kg. In case 
of parallel treatment of normal mice, these parameters were 
slightly changed from normal values and after 25 days of the 
initial treatment they were restored to almost normal values 
(Table 1 and 2). The extract at dose 8 mg/kg also enhanced 
both the peritoneal cells and the number of macrophages to 
some extent in normal mice (Table 3).
  LD50 value in Swiss albino mice was 250 mg/kg. The brine 
shrimp lethality bioassay was done to assess the in vitro 
cytotoxic effect of the compound. Medium lethal concentration 
(LC50) of brine shrimp lethality was 14.07 毺g/mL.
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4. Discussion 
  The results showed that the EEAC at dose 8 mg/kg can 
inhibit cell growth of tumor bearing mice satisfactorily, 
reduce tumor growth rate markedly and increase life span 
dramatically. These are important and promising in justifying 
the potency of a compound in cancer chemotherapy[32]. 
One of the major problems usually encountered in cancer 
chemotherapy is myelosuppression followed by anemia[33,34] 
due to the reduction of RBC and haemoglobin contents. This 
is probably owing to the deficiency of iron of haemolytic 
or myelopathic condition[35].The treatment with EEAC can 
also reverse all depleted haematological parameters back 
towards normal. The host toxic effect of EEAC is not very 
high. In addition the treatment in normal mice increases the 
macrophages and peritoneal cells which is also considered 
as a very vital event in acquiring self destroying activity 
of the living being towards cancer cells[36]. Enhancement 
of macrophages might produce some cytokines such as 
tumor necrosis factors, interleukins etc inside the peritoneal 
cavity, which in turn may be responsible for killing of 
tumor cells[37]. The transplantability of EAC cells shows a 
significant reduction of viability after the treatment with 
EEAC. In addition, since LD50 value of extract is 250 mg/kg as 
compared with the dose (8 mg/kg) used during treatment, the 
plant could be an source of effective anticancer agent with 
low toxicity at doses (up to 8 mg/kg).                                                                                      
  Alpinia genus possess antioxidant properties[38]. Plant 
extracts have vital roles in balancing the intracellular 
oxidant species and antioxidant capability, produces reactive 
oxygen species which are involved in a variety of different 
cellular process ranging from apoptosis and necrosis to cell 
proliferation and carcinogenesis[39]. Natural compounds with 
antioxidants effects are important treatment of cancer[40]. 
More over, antisense glutaminase and inhibition decrease 
glutathione antioxidant capacity and increases apoptosis in 
Ehrlich ascetic tumour cells[41]. This may be attributed to 
the phytoconstituents with antioxidative activity. 
  However, the information obtained from the present 
investigation are insufficient for the crude EEAC. And more 
investigation have to be carried out with crude extract and 
purified compounds using various other cancer cell lines 
and higher animal models, in order to confirm the plant as a 
potent source of anticancer agent.  
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